Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.
Aspartate aminotransferase/Platelets ratio index score
Biomarker
Cirrhosis
Golgi protein-73
Hepatic fibrosis
Hepatitis B
Hepatitis C
Hepatocellular carcinoma
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Sep 2020
14 Sep 2020
Historique:
received:
24
04
2020
revised:
19
05
2020
accepted:
20
08
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Reliable biomarkers of cirrhosis, hepatocellular carcinoma (HCC), or progression of chronic liver diseases are missing. In this context, Golgi protein-73 (GP73) also called Golgi phosphoprotein-2, was originally defined as a resident Golgi type II transmembrane protein expressed in epithelial cells. As a result, GP73 expression was found primarily in biliary epithelial cells, with only slight detection in hepatocytes. However, in patients with acute or chronic liver diseases and especially in HCC, the expression of GP73 is significantly up-regulated in hepatocytes. So far, few studies have assessed GP73 as a diagnostic or prognostic marker of liver fibrosis and disease progression. To assess serum GP73 efficacy as a diagnostic marker of cirrhosis and/or HCC or as predictor of liver disease progression. GP73 serum levels were retrospectively determined by a novel GP73 ELISA (QUANTA Lite Increased serum levels of GP73 (> 20 units) were detected at initial evaluation in 277 out of 632 patients (43.8%). GP73-seropositivity correlated at baseline with the presence of cirrhosis (96.4% GP73 alone appears efficient for detecting cirrhosis and superior to APRI determination. In combination with APRI, its diagnostic performance can be further improved. Most importantly, the simple GP73 measurement proved promising for predicting a worse outcome of patients with both viral and non-viral chronic liver diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Reliable biomarkers of cirrhosis, hepatocellular carcinoma (HCC), or progression of chronic liver diseases are missing. In this context, Golgi protein-73 (GP73) also called Golgi phosphoprotein-2, was originally defined as a resident Golgi type II transmembrane protein expressed in epithelial cells. As a result, GP73 expression was found primarily in biliary epithelial cells, with only slight detection in hepatocytes. However, in patients with acute or chronic liver diseases and especially in HCC, the expression of GP73 is significantly up-regulated in hepatocytes. So far, few studies have assessed GP73 as a diagnostic or prognostic marker of liver fibrosis and disease progression.
AIM
OBJECTIVE
To assess serum GP73 efficacy as a diagnostic marker of cirrhosis and/or HCC or as predictor of liver disease progression.
METHODS
METHODS
GP73 serum levels were retrospectively determined by a novel GP73 ELISA (QUANTA Lite
RESULTS
RESULTS
Increased serum levels of GP73 (> 20 units) were detected at initial evaluation in 277 out of 632 patients (43.8%). GP73-seropositivity correlated at baseline with the presence of cirrhosis (96.4%
CONCLUSION
CONCLUSIONS
GP73 alone appears efficient for detecting cirrhosis and superior to APRI determination. In combination with APRI, its diagnostic performance can be further improved. Most importantly, the simple GP73 measurement proved promising for predicting a worse outcome of patients with both viral and non-viral chronic liver diseases.
Identifiants
pubmed: 32982114
doi: 10.3748/wjg.v26.i34.5130
pmc: PMC7495033
doi:
Substances chimiques
Biomarkers
0
Membrane Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5130-5145Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: This research did not receive any specific grant from funding agencies in the public, commercial, or not -for-profit sectors. However, Inova Diagnostics Inc. provided funds to Norman GL, Shums Z and Albesa R who are employees of Inova (ELISA kits), for the support of this study. All other authors have no disclosures relevant to this manuscript. Other authors have declared that no competing interest exists.
Références
Oncol Lett. 2017 Oct;14(4):3953-3958
pubmed: 28943903
Int J Clin Exp Pathol. 2009;2(1):34-47
pubmed: 18830387
Int J Clin Exp Pathol. 2012;5(9):874-81
pubmed: 23119104
Liver Int. 2017 Nov;37(11):1612-1621
pubmed: 28772348
Oncotarget. 2016 Apr 26;7(17):23530-41
pubmed: 26993603
Gene. 2000 May 16;249(1-2):53-65
pubmed: 10831838
Gut. 2010 Dec;59(12):1687-93
pubmed: 20876776
J Hepatol. 2014 Jul;61(1):28-34
pubmed: 24631902
BMC Cancer. 2012 Jan 16;12:17
pubmed: 22244200
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11379-85
pubmed: 26617863
Mol Med Rep. 2015 Apr;11(4):2644-52
pubmed: 25524053
Asian Pac J Cancer Prev. 2014;15(4):1539-44
pubmed: 24641364
Eur J Intern Med. 2007 Jan;18(1):48-55
pubmed: 17223043
Oncotarget. 2015 Oct 20;6(32):33523-33
pubmed: 26378022
Onco Targets Ther. 2020 Jan 28;13:827-840
pubmed: 32095079
Eur J Intern Med. 2017 Sep;43:e48-e49
pubmed: 28502865
Oncotarget. 2017 Mar 7;8(10):16498-16506
pubmed: 28157705
J Ultrasound Med. 2010 Nov;29(11):1581-8
pubmed: 20966469
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Eur J Intern Med. 2009 Jan;20(1):35-43
pubmed: 19237090
Am J Gastroenterol. 2004 Jun;99(6):1087-95
pubmed: 15180730
World J Gastroenterol. 2005 Jan 28;11(4):482-7
pubmed: 15641130
Oncotarget. 2016 Apr 19;7(16):21404-15
pubmed: 26870893
J Gastroenterol. 2010 Dec;45(12):1272-82
pubmed: 20625772
World J Gastroenterol. 2014 Aug 28;20(32):11287-96
pubmed: 25170213
J Hepatol. 2020 Jun;72(6):1088-1096
pubmed: 31981727
Clin Lab. 2017 Nov 1;63(11):1903-1909
pubmed: 29226636
PLoS One. 2014 Mar 07;9(3):e90553
pubmed: 24608522
Hepatol Res. 2013 Nov;43(11):1199-210
pubmed: 23607749
Hepatol Int. 2013 Mar;7(1):59-64
pubmed: 23519638
Oncotarget. 2017 Jul 17;8(46):80521-80530
pubmed: 29113322
Gastroenterology. 2015 Sep;149(3):741-52.e14
pubmed: 25980751
PLoS One. 2015 Oct 06;10(10):e0140067
pubmed: 26441340
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 2002 Jun;35(6):1431-40
pubmed: 12029628
J Viral Hepat. 2015 Feb;22(2):120-7
pubmed: 25040685
Cell Biosci. 2012 Sep 10;2(1):31
pubmed: 22958594
Hepat Mon. 2015 Dec 29;15(12):e32918
pubmed: 26977166
Clin Rev Allergy Immunol. 2018 Apr;54(2):282-294
pubmed: 29256057
J Hepatol. 2016 Apr;64(4):800-6
pubmed: 26678008
Hepatology. 2019 Sep;70(3):851-870
pubmed: 30723919
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Eur J Intern Med. 2017 Mar;38:83-88
pubmed: 28100410
J Gastroenterol Hepatol. 2011 Jul;26(7):1207-12
pubmed: 21443671
J Viral Hepat. 2017 Nov;24 Suppl 1:57-65
pubmed: 29082644
PLoS One. 2014 Jul 17;9(7):e100187
pubmed: 25033446
Clin Biochem. 2014 Nov;47(16-17):216-22
pubmed: 25168922
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
World J Hepatol. 2015 Jul 18;7(14):1875-83
pubmed: 26207169